ClinicalTrials.gg
RecruitingNCT07575308HMBeaconUpdated Nov 13, 2026

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

A Phase 2 interventional study of ALN-6400 in Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB), sponsored by Alnylam Pharmaceuticals. Recruiting at 29 sites in 6 countries. Open to female participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 13, 2026First sites in Turkey (Türkiye) and GermanySite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 38 studies in von Willebrand Diseases with a site in United States — 11 open to participants now, 12 under way, 2 of them phase 3. von Willebrand Diseases · United States.

Planned enrollment
13th of 22
24 · median 30
Started
2026
the only one that year
Phase 2
5 of 38
1 open now
Primary completion
2027-06
later than 3 of 11 live
Registered
38th of 38
by date
Lead sponsor
1 of 38
Alnylam Pharmaceuticals

Among the 38 studies in von Willebrand Diseases with a site in United States, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, reaches primary completion later than 3 of the 11 other live ones, and was the 38th registered.

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

Browse von Willebrand Diseases studies →

Open to participants now

11 of the 38 studies in von Willebrand Diseases with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in von Willebrand Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

03

Conditions studied

  • Von Willebrand Disease (VWD)
  • Heavy Menstrual Bleeding (HMB)

Keywords

  • siRNA, RNAi therapeutic, Plasminogen, PLG, VWD, HMB
04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and -type VWD) and HMB for 2 cycles during screening

Exclusion criteria

Exclusion Criteria -

  • Has (ALT) or aspartate aminotransferase (AST) greater than 2 times the (ULN)
  • Has total greater than 1.5×ULN (except for patients with Gilbert's syndrome)
  • Has an estimated glomerular filtration () less than 30 mL/min/1.73m\^2 at screening
  • Is not willing to comply with the requirements during the study period
  • Used routine factor prophylaxis (greater than or equal to 1 infusion of factor per week over 12 weeks) within 4 weeks of screening or plans use for routine factor prophylaxis during the study
  • New placement of any hormonal or nonhormonal intrauterine device (IUD) or hormonal implants within 24 weeks of screening
  • Known current gynecological conditions causing abnormal uterine bleeding (including infection, fibroids, endometriosis, polycystic ovary syndrome, or dysplasia)

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    ALN-6400 (Treatment Group A)

    Participants will be administered multiple doses of ALN-6400.

    Drug: ALN-6400

  • Experimental
    ALN-6400 (Treatment Group B)

    Participants will be administered multiple doses of ALN-6400.

    Drug: ALN-6400

Interventions

  • DrugALN-6400

    ALN-6400 will be administered subcutaneously (SC).

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Time frame: Up to Week 72

Secondary outcomes

  1. Change from Baseline in Plasminogen (PLG) Plasma Activity Levels

    Time frame: Screening and up to Week 72 postdose

  2. Change from Baseline in PLG Plasma Protein Levels

    Time frame: Screening and up to Week 72 postdose

  3. Change from Baseline in Menstrual Blood Loss Via Pictorial Blood Assessment Chart (PBAC)

    Time frame: Screening and up to Week 72 postdose

  4. Patient-reported Outcome (PRO) assessed by Patient Global Impression of Change (PGI-C) Score

    Time frame: Week 4 up to Week 72

  5. Change from Baseline in PRO assessed by Patient Global Impression of Severity (PGI-S) Score

    Time frame: Baseline up to Week 72

07

Study locations

1 of 29 sites recruiting
  • Clinical Trial Site
    Orange, California 92868, United States
    Not yet recruiting
  • Clinical Trial Site
    San Diego, California 92123, United States
    Not yet recruiting
  • Clinical Trial Site
    San Francisco, California 94143, United States
    Not yet recruiting
  • Clinical Trial Site
    Miami, Florida 33143, United States
    Recruiting
  • Clinical Trial Site
    Augusta, Georgia 30912, United States
    Not yet recruiting
  • Clinical Trial Site
    Lexington, Kentucky 40536, United States
    Not yet recruiting
  • Clinical Trial Site
    Chapel Hill, North Carolina 27514, United States
    Not yet recruiting
  • Clinical Trial Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Clinical Trial Site
    Pittsburgh, Pennsylvania 15213, United States
    Not yet recruiting
  • Clinical Trial Site
    Charleston, South Carolina 29425, United States
    Not yet recruiting
  • Clinical Trial Site
    Bad Homburg, 61352, Germany
    Not yet recruiting
  • Clinical Trial Site
    Berlin, 10249, Germany
    Not yet recruiting
  • Clinical Trial Site
    Duisburg, 47051, Germany
    Not yet recruiting
  • Clinical Trial Site
    Frankfurt am Main, 60590, Germany
    Not yet recruiting
  • Clinical Trial Site
    Nijmegen, 6525 GA, Netherlands
    Not yet recruiting
  • Clinical Trial Site
    Utrecht, 3584 CX, Netherlands
    Not yet recruiting
  • Clinical Trial Site
    Stockholm, 171 76, Sweden
    Not yet recruiting
  • Clinical Trial Site
    Istanbul, 34093, Turkey (Türkiye)
    Not yet recruiting
  • Clinical Trial Site
    Izmir, 35000, Turkey (Türkiye)
    Not yet recruiting
  • Clinical Trial Site
    Izmir, 35040, Turkey (Türkiye)
    Not yet recruiting
  • Clinical Trial Site
    Samsun, 55200, Turkey (Türkiye)
    Not yet recruiting
  • Clinical Trial Site
    Şahinbey, 27070, Turkey (Türkiye)
    Not yet recruiting
  • Clinical Trial Site
    Birmingham, B15 2GW, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    Bradford, BD9 6RJ, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    London, E1 1FR, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    London, NW3 2QG, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    London, SE1 7EH, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    Oxford, OX3 7HE, United Kingdom
    Not yet recruiting
  • Clinical Trial Site
    Truro, TR1 3LJ, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Phase 2-4: Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the United States (US) and/or the European Union (EU). Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Aug 2029, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 30, 2029was Nov 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added — first sites in Turkey (Türkiye) and Germany. 5 sites changed recruiting status (5 now not yet recruiting)
Show 5 sites
  • Clinical Trial Site · Orange, United StatesRecruiting→Not yet recruiting
  • Clinical Trial Site · San Diego, United StatesRecruiting→Not yet recruiting
  • Clinical Trial Site · San Francisco, United StatesRecruiting→Not yet recruiting
  • Clinical Trial Site · Lexington, United StatesRecruiting→Not yet recruiting
  • Clinical Trial Site · Pittsburgh, United StatesRecruiting→Not yet recruiting
Show 18 added (5 Turkey (Türkiye), 4 United States, 4 United Kingdom, 4 Germany, 1 Netherlands)
  • Clinical Trial Site · Augusta, United States
  • Clinical Trial Site · Chapel Hill, United States
  • Clinical Trial Site · Cleveland, United States
  • Clinical Trial Site · Charleston, United States
  • Clinical Trial Site · Utrecht, Netherlands
  • Clinical Trial Site · Istanbul, Turkey (Türkiye)
  • Clinical Trial Site · Samsun, Turkey (Türkiye)
  • Clinical Trial Site · Şahinbey, Turkey (Türkiye)
  • Clinical Trial Site · Birmingham, United Kingdom
  • Clinical Trial Site · London, United Kingdom
  • Clinical Trial Site · Bad Homburg, Germany
  • Clinical Trial Site · Berlin, Germany
  • Clinical Trial Site · Duisburg, Germany
  • Clinical Trial Site · Frankfurt am Main, Germany
  • Clinical Trial Site · Izmir, Turkey (Türkiye)
  • Clinical Trial Site · Izmir, Turkey (Türkiye)
  • Clinical Trial Site · London, United Kingdom
  • Clinical Trial Site · London, United Kingdom
across 2 updates, Oct 26, 2026 – Nov 13, 2026
Study completion
Nov 29, 2028→Aug 30, 2029
Oct 26, 2026
Show all 2 updates
  1. Nov 13, 2026
    8 sites added — first site in Germany
    Show 8 added (4 Germany, 2 Turkey (Türkiye), 2 United Kingdom)
    • Clinical Trial Site · Bad Homburg, Germany
    • Clinical Trial Site · Berlin, Germany
    • Clinical Trial Site · Duisburg, Germany
    • Clinical Trial Site · Frankfurt am Main, Germany
    • Clinical Trial Site · Izmir, Turkey (Türkiye)
    • Clinical Trial Site · Izmir, Turkey (Türkiye)
    • Clinical Trial Site · London, United Kingdom
    • Clinical Trial Site · London, United Kingdom
    + 1 other change: verification date
  2. Oct 26, 2026
    10 sites added — first site in Turkey (Türkiye). 5 sites changed recruiting status (5 now not yet recruiting)
    Show 5 sites
    • Clinical Trial Site · Orange, United StatesRecruiting→Not yet recruiting
    • Clinical Trial Site · San Diego, United StatesRecruiting→Not yet recruiting
    • Clinical Trial Site · San Francisco, United StatesRecruiting→Not yet recruiting
    • Clinical Trial Site · Lexington, United StatesRecruiting→Not yet recruiting
    • Clinical Trial Site · Pittsburgh, United StatesRecruiting→Not yet recruiting
    Show 10 added (4 United States, 3 Turkey (Türkiye), 2 United Kingdom, 1 Netherlands)
    • Clinical Trial Site · Augusta, United States
    • Clinical Trial Site · Chapel Hill, United States
    • Clinical Trial Site · Cleveland, United States
    • Clinical Trial Site · Charleston, United States
    • Clinical Trial Site · Utrecht, Netherlands
    • Clinical Trial Site · Istanbul, Turkey (Türkiye)
    • Clinical Trial Site · Samsun, Turkey (Türkiye)
    • Clinical Trial Site · Şahinbey, Turkey (Türkiye)
    • Clinical Trial Site · Birmingham, United Kingdom
    • Clinical Trial Site · London, United Kingdom
    Study completion Nov 29, 2028→Aug 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07575308
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Jul 30, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion